Use of Teriparatide to Accelerate Fracture Healing

• Status: Terminated
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effect of the drug teriparatide to the effect of placebo on pelvic fracture healing.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Rochester
• Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institutes of Health (NIH)
• Treatments: Teriparatide

Criteria

Inclusion Criteria:

• Females must be menopausal (no menses within the last 12 months)

• Low energy fragility fractures of the pelvis, including anterior column, posterior column, inferior or superior rami, or sacrum

• Maximum of 2 weeks post fracture

• Mental status consistent with completing the study protocol

Exclusion Criteria:

• Currently receiving any treatment for osteoporosis, including estrogen and estrogenic-like compounds

• Received radiation treatment to any site at any time in the past

• Received chemotherapy for cancer at any time in the past

• Any active cancer

• Surgical repair (or attempted repair) of the fracture site in the pelvis

• Use of any bone-active medications

• Use of anticonvulsant therapy

• Use of immunosuppressants

• Any renal, gastrointestinal, liver, or metabolic bone disease

• Pregnancy

• High calcium, parathyroid hormone, or alkaline phosphatase, as based on laboratory results